- Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. N Engl J Med 1997; 337: 734–9.
- Gisslén M, Norkrans G, Svennerholm B, Hagberg L. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir. AIDS 1998; 12: 114–6.
- Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active anti-retroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863–8.
- Sebire K, McGavin K, Land S, Middleton T, Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol 1998; 36: 493–8.
- Gisslén M, Norkrans G, Svennerholm B, Hagberg L. The effect on cerebrospinal fluid HIV RNA levels after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434–7.
- Perelson AS, Essunger P, Cao YZ, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188–91.
- Gisslén M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immun Defic Syndr 1999; 21: 271–6.
- Martin C, Albert J, Hansson P, Pehrsson P, Link H, Sönnerborg A. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immun Defic Syndr Hum Retrovirol 1998; 17: 214–9.
- Gisslén M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B. Cerebrospinal fluid viral load in HIV-1-infected patients without anti-retroviral treatment: a longitudinal study. J Acquir Immun Defic Syndr Hum Retrovirol 1998; 17: 291–5.
- Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to anti-retroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999; 13: 1051–61.
- Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol 1995; 33: 352–5.
- Di Stefano M, Monno L, Fiore JR, Buccoliero G, Appice A, Perulli LM, et al. Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS 1998; 12: 737–43.
- Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJS, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997; 71: 2059–71.
- Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175: 963–6.
- McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689–98.
- Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998; 12: 389–94.
- Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Hermann SA, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998; 8: 277–84.
- Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks CH, Bult A, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581–7.
- Burger DM, Kraayeveld CL, Meenhorst PL, Mulder JW, Hoetelmans RM, Koks CH, et al. Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci 1995; 17: 218–21.
- Foudraine NA, Hoetelmans RMW, Lange JMA, de Wolf F, van Benthem BHB, Mass JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547–51.
- Ståhle L, Martin C, Svensson JO, Sönnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet 1997; 350: 1823.
- Moyle GJ, Sadler M, Buss N. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination anti-retroviral therapy. Clin Infect Dis 1999; 28: 403–4.
- Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immun Defic Syndr Hum Retrovirol 1999; 20: 39–43.
- Groothuis DR, Levy RM. The entry of antiviral and anti-retroviral drugs into the central nervous system. J NeuroVirology 1997; 3: 387–400.
Scandinavian Journal of Infectious Diseases
Volume 32, 2000 - Issue 4